This is promising evidence for PARP14’s role in host defense against SARS-CoV-2; IFN-1 treatment is often proposed as a candidate treatment during viral infection [13]. The sensitivity of SARS-CoV (using the human coronavirus 229E) to IFN-α treatment was also increased when the coronavirus macrodomain was attenuated [12]. This evidence concerns the gene PARP14 and viral infectious disease.